HCA Healthcare, Inc. is a leading healthcare provider that operates hospitals and related healthcare entities across the United States and England . The company owns and manages a network of 188 hospitals, 125 freestanding surgery centers, and 23 freestanding endoscopy centers, offering a wide range of outpatient and ancillary services . HCA's facilities include general acute care hospitals, behavioral hospitals, and various outpatient facilities, providing comprehensive medical services such as surgery, emergency care, and diagnostics . The company is structured into three geographic groups: the American, Atlantic, and National Groups, each contributing to its diversified service line approach .
- American Group - Operates hospitals and healthcare facilities in various states, providing a broad spectrum of medical services and contributing significantly to the company's revenue.
- Atlantic Group - Manages healthcare facilities across different regions, offering extensive inpatient and outpatient services, including emergency and diagnostic care.
- National Group - Comprises hospitals and related entities, delivering a wide range of healthcare services and supporting the company's balanced revenue mix.
- General Acute Care Hospitals - Provides comprehensive medical and surgical services, including intensive care, cardiac care, and emergency services.
- Behavioral Hospitals - Offers specialized care for mental health and behavioral disorders.
- Outpatient Facilities - Includes ambulatory surgery centers, emergency care facilities, urgent care facilities, and diagnostic centers, enhancing community healthcare networks.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Christopher F. Wyatt Executive | SVP and Controller | None | Controller since April 2016; joined HCA in 2010; set to assume the role of Principal Accounting Officer effective May 1, 2024. | |
Jennifer L. Berres Executive | SVP and Chief Human Resources Officer | None | Chief Human Resources Officer since November 1, 2019; joined HCA in 1993; instrumental in developing the HCA Leadership Institute. | |
Jon M. Foster Executive | EVP and Chief Operating Officer | None | COO since January 1, 2023; joined HCA in 2001; previously President of American Group and CEO of St. David’s HealthCare. | |
Michael A. Marks Executive | Executive Vice President and CFO | None | CFO of HCA since May 1, 2024; joined HCA in 1996; previously served as SVP – Finance and CFO of the National Group. | |
Michael R. McAlevey Executive | EVP – Chief Legal and Administrative Officer | None | Chief Legal and Administrative Officer since April 1, 2024; joined HCA in January 2022; previously held senior legal roles at GE and the SEC. | |
Michael S. Cuffe, M.D. Executive | EVP and Chief Clinical Officer | None | Chief Clinical Officer since January 1, 2022; joined HCA in 2011; previously President of Physician Services Group. | |
Sammie S. Mosier Executive | SVP and Chief Nurse Executive | None | Chief Nurse Executive since December 1, 2021; joined HCA in 1992 as a bedside nurse; previously VP and Assistant Chief Nursing Executive. | |
Samuel N. Hazen Executive | Chief Executive Officer | None | CEO of HCA since January 2019; joined HCA in the mid-1980s; held various leadership roles, including COO and President. | View Report → |
Andrea B. Smith Board | Director | Board member of PGA of America and Charlotte Sports Foundation | Director at HCA since 2022; retired from Bank of America in 2021 as Chief Administrative Officer. | |
Hugh F. Johnston Board | Director | Director at Microsoft Corporation; Member of multiple advisory boards | Director at HCA since 2021; extensive financial expertise; previously Vice Chairman and CFO of PepsiCo. | |
Meg G. Crofton Board | Director | Director at Cracker Barrel Old Country Store, Inc. | Director at HCA since 2019; retired from The Walt Disney Company in 2015 after serving as President of Walt Disney World and Disney’s Parks and Resorts Operations. | |
Michael W. Michelson Board | Director | Director at Zimmer Biomet Holdings, Inc. | Director at HCA since 2018; previously a senior partner at KKR; extensive experience in healthcare investments. | |
Nancy-Ann DeParle Board | Director | Co-founder and Managing Partner of Consonance Capital Partners; Director at CVS Health Corporation | Director at HCA since 2014; extensive experience in healthcare policy and government relations. | |
Robert J. Dennis Board | Director | Director at CoreCivic, Inc. | Director at HCA since 2014; extensive experience as a CEO and director of public companies. | |
Thomas F. Frist III Board | Chairman of the Board | Director at Verisign, Inc.; Founder of Frist Capital, LLC | Chairman of HCA's Board since 2006; significant shareholder; extensive experience in healthcare and corporate finance. | |
William R. Frist Board | Director | Chair and President of the Board of Trustees of the Frist Art Museum; Director at The Frist Foundation | Director at HCA since 2009; principal of Champion & Co. Inc.; significant healthcare and investment expertise. |
-
Given the significant impact of recent hurricanes on HCA's operations, including the closure of HCA Florida Largo Hospital and ongoing issues at HCA Mission Hospital, how do you plan to mitigate the financial and operational risks associated with natural disasters, and has this influenced your long-term capital allocation strategy?
-
With Medicaid adjusted admissions declining by 8.5% due to redeterminations, and considering Medicaid accounts for 17%-18% of your adjusted admissions, what specific strategies are you implementing to offset this volume decline and potential revenue impact?
-
Despite your investments in AI and technology, which are still in early stages and not yet yielding material results, can you provide more details on the expected timeline for these initiatives to significantly enhance operational efficiency and how you plan to measure their success?
-
As wage rates have stabilized in the 2.5% to 3.5% range but labor costs remain a challenge, what additional measures are you taking to optimize labor expenses and improve your wage and compensation expense ratio?
-
In light of pressures on Medicare Advantage plan rates and margins, how are you addressing potential reimbursement challenges in your contracts with MA plans, and what changes do you anticipate in your contracting strategy to ensure sustainable revenue growth?
Research analysts who have asked questions during HCA Healthcare earnings calls.
Andrew Mok
Barclays
6 questions for HCA
Ann Hynes
Mizuho Financial Group
6 questions for HCA
Joshua Raskin
Nephron Research
6 questions for HCA
Pito Chickering
Deutsche Bank
6 questions for HCA
Ryan Langston
TD Cowen
6 questions for HCA
Brian Tanquilut
Jefferies
5 questions for HCA
Justin Lake
Wolfe Research, LLC
5 questions for HCA
Matthew Gillmor
KeyCorp
5 questions for HCA
Lance Wilkes
Sanford C. Bernstein & Co., LLC
4 questions for HCA
Sarah James
Cantor Fitzgerald
4 questions for HCA
Scott Fidel
Stephens Inc.
4 questions for HCA
Whit Mayo
Leerink Partners
4 questions for HCA
A.J. Rice
UBS Group AG
3 questions for HCA
Albert Rice
UBS
3 questions for HCA
Ben Hendrix
RBC Capital Markets
3 questions for HCA
Benjamin Hendrix
RBC Capital Markets
3 questions for HCA
Craig Hettenbach
Morgan Stanley
3 questions for HCA
Joanna Gajuk
Bank of America
3 questions for HCA
Raj Kumar
Stephens
3 questions for HCA
Stephen Baxter
Wells Fargo & Company
3 questions for HCA
Benjamin Mayo
Leerink Partners
2 questions for HCA
Benjamin Rossi
JPMorgan Chase & Co.
2 questions for HCA
Ben Rossi
JPMorgan Chase & Co.
2 questions for HCA
Jamie Perse
The Goldman Sachs Group, Inc.
2 questions for HCA
Jason Cassorla
Guggenheim Partners
2 questions for HCA
John Ransom
Raymond James
2 questions for HCA
Stephen Baxter
Wells Fargo
2 questions for HCA
Anna Barsanti
Wolfe Research, LLC
1 question for HCA
Craig Haughton
Morgan Stanley
1 question for HCA
Kevin Fischbeck
Bank of America
1 question for HCA
Meghan Holtz
Jefferies Financial Group Inc.
1 question for HCA
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Hospital facilities in Texas | 2024 | HCA Healthcare acquired multiple hospital facilities in Texas, paying $50 million in Q1, another $50 million for two facilities in the six‐month period, and $112 million for three facilities (one effective October 1, 2024), as part of its strategic expansion of healthcare services; the purchase prices were allocated based on the fair values of the assets and liabilities assumed. |
Nonhospital health care entities | 2024 | HCA Healthcare expanded its nonhospital health care portfolio by acquiring entities in Q1 for $46 million, adding $35 million in Q2 (totaling $81 million for six months), and paying $31 million in Q3 for a cumulative $112 million, reinforcing its strategy to extend services beyond traditional hospitals. |
Hospital facility in Texas | 2023 | In 2023, HCA Healthcare acquired a hospital facility in Texas for $83 million, with the transaction completed in the quarter ended March 31 and effective April 1, supporting its facility expansion strategy. |
Non-hospital healthcare entities | 2023 | HCA Healthcare’s 2023 acquisitions of non-hospital healthcare entities involved spending $32 million in Q1, $41 million in Q2, and a cumulative total of $198 million by Q3, with the purchase price allocated to assets and liabilities at fair value to bolster its service capabilities. |
Davie Medical Center, LLC | 2022 | Although specific acquisition deal terms were not disclosed, Davie Medical Center, LLC became a subsidiary guarantor for several senior secured notes (due 2039, 2049, 2031, and 2051), reflecting its involvement in HCA’s financing structure. |
Springfield Health Services, LLC | 2022 | No detailed acquisition terms were provided for Springfield Health Services, LLC; however, it is noted as a subsidiary guarantor in supplemental indentures for senior secured notes, indicating its strategic role in the financing arrangement. |
Recent press releases and 8-K filings for HCA.
- HCA Inc., a wholly owned subsidiary of HCA Healthcare, proposes a public offering of senior unsecured notes, with terms (maturity, interest rate, principal) to be determined by market conditions; net proceeds are intended for general corporate purposes, including repayment of its $4.0 billion commercial paper program and potential redemption of outstanding notes.
- The issuer has elected to redeem all $1.5 billion of its 5.875% senior notes due 2026 on November 26, 2025, subject to receipt of offering proceeds.
- Revenue of $19.16B in Q3 2025, with net income of $1.64B, marking solid year-over-year growth.
- Non-GAAP EPS of $6.96, a 23.19% earnings surprise.
- Raised full-year 2025 revenue guidance to $75.0–$76.5B and EPS guidance to $27.00–$28.00.
- Declared a quarterly cash dividend of $0.72 per share for December 2025.
- Recorded 9.6% revenue growth and 42% adjusted diluted EPS increase in Q3 2025 versus prior year, driven by volume gains, improved payer mix, and Medicaid supplemental programs.
- Same-facility equivalent admissions rose 2.4%, inpatient surgical volume 1.4%, outpatient surgical volume 1.1%, and visits 1.3%, with net revenue per admission benefiting from payer mix, dispute resolution, and a $240 million boost from state supplemental payments.
- Generated $4.4 billion of operating cash flow in Q3, deploying $2.5 billion to share repurchases, $1.3 billion in capital expenditures, and $166 million in dividends.
- Raised full-year 2025 outlook: revenues of $75.0–76.5 billion, net income of $6.50–6.72 billion, adjusted EBITDA of $15.25–15.65 billion, diluted EPS of $27–28, and capital spending of ~$5 billion; anticipates $250–350 million net benefit from supplemental programs.
- HCA Healthcare delivered 9.6% revenue growth and a 42% increase in adjusted diluted EPS in Q3 2025 versus prior year.
- Same-facility equivalent admissions rose 2.4%, with inpatient surgical volume up 1.4% and outpatient surgical volume up 1.1% year-over-year.
- Updated full-year 2025 guidance to $75.0–76.5 billion in revenues, $15.25–15.65 billion in adjusted EBITDA, and $27–28 in diluted EPS.
- Generated $4.4 billion of operating cash flow, deployed $2.5 billion to share repurchases and paid $166 million in dividends in the quarter.
- HCA delivered 9.6% revenue growth and 42% adjusted EPS growth in Q3 2025, driven by broad-based volume gains, improved payer mix and Medicaid supplemental programs.
- Same-facility equivalent admissions rose 2.4%, inpatient surgical volume was up 1.4%, outpatient surgical volume up 1.1%, and same-facility visits increased 1.3% year-over-year.
- Medicaid state supplemental payments contributed $240 million of net benefit in Q3 2025, accounting for roughly half of the increase in net revenue per equivalent admission.
- Full-year 2025 guidance was raised to $75.0–76.5 billion in revenues, $6.50–6.72 billion in net income, $15.25–15.65 billion in adjusted EBITDA, and $27–28 in diluted EPS.
- Preliminary outlook for 2026 anticipates 2–3% volume growth and stable operating cost trends, with formal guidance to be provided in Q4 2025.
- Revenue rose 9.6% and adjusted diluted EPS grew 42% year-over-year in Q3 2025.
- Q3 volumes: same-facility equivalent admissions +2.4%, inpatient surgical +1.4%, outpatient surgical +1.1%, and ER visits +1.3% versus prior year.
- Raised FY 2025 guidance: revenue $75.0–76.5 B, net income $6.5–6.72 B, adjusted EBITDA $15.25–15.65 B, diluted EPS $27–28, and capex ~$5 B.
- Medicaid supplemental payments boosted Q3 adjusted EBITDA by ~$240 M; full-year net benefit now expected $250–350 M (Q4 down $120 M), and Q4 hurricane recovery to add $100 M EBITDA.
- Q3 cash flow from operations $4.4 B, with $1.3 B in capex, $2.5 B in share repurchases, and $166 M in dividends.
- Revenues of $19.161 billion in Q3 2025, up 9.6% YoY; net income of $1.643 billion (+29.4%) and diluted EPS of $6.96 (+42.6%)
- Adjusted EBITDA of $3.870 billion, an 18.5% increase, and cash flows from operating activities of $4.416 billion (Q3 2024: $3.515 billion)
- 2025 guidance raised: revenues to $75.0–$76.5 billion, net income to $6.495–$6.715 billion, adjusted EBITDA to $15.25–$15.65 billion, and diluted EPS to $27.00–$28.00
- Quarterly dividend of $0.72 per share declared, payable December 29, 2025
- HCA Healthcare reported Q3 2025 revenues of $19.161 B (+9.6% YoY), net income of $1.643 B (+29.4%), and diluted EPS of $6.96 (+42.6%).
- Adjusted EBITDA rose 18.5% to $3.870 B, while operating cash flow increased to $4.416 B, up from $3.515 B in Q3 2024.
- The company raised full-year 2025 guidance to $75.0–$76.5 B in revenues, $6.495–$6.715 B in net income, $15.25–$15.65 B in adjusted EBITDA, and $27.00–$28.00 in diluted EPS.
- In Q3, HCA repurchased 6.514 M shares for $2.498 B, leaving $3.256 B available under its buyback authorization.
- HCA Inc., a wholly owned subsidiary of HCA Healthcare, Inc., established an unsecured commercial paper program with a maximum aggregate face amount of $4.0 billion.
- The program allows notes with maturities up to 397 days to be issued for general corporate purposes and is unconditionally guaranteed by the Parent Guarantor.
- Strong Q1 performance with solid volume growth, margin improvement, and 11% EBITDA growth (nearly 9% when excluding certain state benefits), leading to a reaffirmation of full-year guidance.
- Emphasis on operational excellence including consistent 3% net revenue per unit growth, cost management, and overall strong fundamentals despite external headwinds.
- Continued focus on workforce optimization through improved retention (near pre-pandemic levels) and aggressive expansion of the Galen School of Nursing program (growing from 4 to 22 campuses, nearing 20,000 students) to support staffing needs.
- Progress in contracting with over 90% contracted for 2025, supported by steady payer renewals and mid-single digit rate increases across service lines.